Overview
McDermott Will & Emery has advised Cilcare, a biotech company specializing in hearing sciences, on the completion of a EUR 40 million Series A round to accelerate the development of innovative treatments for early hearing loss.
The round brought together new investors SHIONOGI & CO LTD, Sprim Global Investments Pte. Ltd, as well as long-standing investors Sofilaro, ARIS, SudPME and UVM Health Capital.
This financing will enable Cilcare to initiate two Phase 2a clinical trials in 2025, in Europe and the United States, for its lead candidate, CIL001, a treatment targeting cochlear synaptopathy.
The McDermott team on this transaction comprised :
- Emmanuelle Trombe, Partner
- Shirin Deyhim, Partner
- Hugo Lamour and Natacha Vasak, associates
